Models of retinal diseases and their applicability in drug discovery

Expert Opinion on Drug Discovery

Volumn 13, Issue 4, 2018, Pages 359-377

  Malek, Goldis ^a   Busik, Julia ^b   Grant, Maria B ^c   Choudhary, Mayur ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Age related macular degeneration; animal models; cell culture models; diabetic retinopathy

Indexed keywords

AGE RELATED MACULAR DEGENERATION; DIABETIC RETINOPATHY; HUMAN; IMMUNE DYSREGULATION; IN VITRO STUDY; IN VIVO STUDY; LIPID METABOLISM; LIPID TRANSPORT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT; ADULT; AGED; ANIMAL; DISEASE MODEL; DRUG DESIGN; DRUG DEVELOPMENT; MACULAR DEGENERATION; PATHOPHYSIOLOGY; PROCEDURES;

ADULT; AGED; ANIMALS; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MACULAR DEGENERATION;

EID: 85043528321     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2018.1430136     Document Type: Review

References (261)

1. Parr T, Friston KJ., The active construction of the visual world. Neuropsychologia. 2017;104:92–101.
2. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J Med. 2000;342(7):483–492.
3. Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care. 2003;26(1):226–229.
4. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116.
5. Zheng Y, He M, Congdon N., The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428–431.
6. Eyetech Study G. Preclinical and phase 1a clinical evaluation of an anti-VEGF pegylated aptamer (eye001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22(2):143–152.
7. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye. 2011;25(6):661–672.
8. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–1239.
9. Staton CA, Reed MW, Brown NJ. A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol. 2009;90(3):195–221.
10. Antonetti DA, Barber AJ, Khin S, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998;47(12):1953–1959.
11. Bullard SR, Hatchell DL, Cohen HJ, et al. Increased adhesion of neutrophils to retinal vascular endothelial cells exposed to hyperosmolarity. Exp Eye Res. 1994;58(6):641–647.
12. Chibber R, Molinatti PA, Rosatto N, et al. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia. 1997;40(2):156–164.
13. Connell P, Walshe T, Ferguson G, et al. Elevated glucose attenuates agonist- and flow-stimulated endothelial nitric oxide synthase activity in microvascular retinal endothelial cells. Endothelium. 2007;14(1):17–24.
14. Elayappan B, Ravinarayannan H, Pasha SP, et al. PEDF inhibits Vegf- and EPO-induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis. 2009;12(4):313–324.
15. Fernandes R, Girao H, Pereira P. High glucose down-regulates intercellular communication in retinal endothelial cells by enhancing degradation of connexin 43 by a proteasome-dependent mechanism. J Biol Chem. 2004;279(26):27219–27224.
16. Gardner TW, Lieth E, Khin SA, et al. Astrocytes increase barrier properties and zo-1 expression in retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 1997;38(11):2423–2427.
17. Giannini S, Cresci B, Manuelli C, et al. Insulin-like growth factor binding protein production in bovine retinal endothelial cells. Metabolism. 1997;46(12):1367–1379.
18. King GL, Buzney SM, Kahn CR, et al. Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest. 1983;71(4):974–979.
19. Knott RM, Robertson M, Forrester JV. Regulation of glucose transporter (GLUT 3) and aldose reductase mRNA in bovine retinal endothelial cells and retinal pericytes in high glucose and high galactose culture. Diabetologia. 1993;36(9):808–812.
20. Lee TS, MacGregor LC, Fluharty SJ, et al. Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest. 1989;83(1):90–94.
21. Li W, Liu X, Yanoff M, et al. Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia. 1996;39(5):537–547.
22. Lyons TJ, Li W, Wells-Knecht MC, et al. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes. 1994;43(9):1090–1095.
23. Mamputu JC, Renier G. Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. J Diabetes Complications. 2002;16(4):284–293.
24. Sheikpranbabu S, Haribalaganesh R, Banumathi E, et al. Pigment epithelium-derived factor inhibits advanced glycation end-product-induced angiogenesis and stimulates apoptosis in retinal endothelial cells. Life Sci. 2009;85(21–22):719–731.
25. Sone H, Deo BK, Kumagai AK. Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. Invest Ophthalmol Vis Sci. 2000;41(7):1876–1884.
26. Thieme H, Aiello LP, Takagi H, et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 1995;44(1):98–103.
27. Wu H, Xia X, Jiang C, et al. High glucose attenuates insulin-induced VEGF expression in bovine retinal microvascular endothelial cells. Eye. 2010;24(1):145–151.
28. Busik JV, Mohr S, Grant MB. Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes. 2008;57(7):1952–1965.
29. Cai J, Ahmad S, Jiang WG, et al. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes. 2003;52(12):2959–2968.
30. Chen W, Esselman WJ, Jump DB, et al. Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 2005;46(11):4342–4347.
31. Chen W, Jump DB, Grant MB, et al. Dyslipidemia, but not hyperglycemia, induces inflammatory adhesion molecules in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 2003;44(11):5016–5022.
32. Ding Y, Hu Z, Luan J, et al. Protective effect of miR-200b/c by inhibiting vasohibin-2 in human retinal microvascular endothelial cells. Life Sci. 2017;191:245–252.
33. Fernandes R, Hosoya K, Pereira P. Reactive oxygen species downregulate glucose transport system in retinal endothelial cells. Am J Physiol Cell Physiol. 2011;300(4):C927–C936.
34. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept. 1993;48(1–2):267–278.
35. Grant MB, Guay C. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest Ophthalmol Vis Sci. 1991;32(1):53–64.
36. Ibrahim AS, Saleh H, El-Shafey M, et al. Targeting of 12/15-lipoxygenase in retinal endothelial cells, but not in monocytes/macrophages, attenuates high glucose-induced retinal leukostasis. Biochim Biophys Acta. 2017;1862(6):636–645.
37. Kady N, Yan Y, Salazar T, et al. Increase in acid sphingomyelinase level in human retinal endothelial cells and CD34+ circulating angiogenic cells isolated from diabetic individuals is associated with dysfunctional retinal vasculature and vascular repair process in diabetes. J Clin Lipidol. 2017;11(3):694–703.
38. Ma J, Liu T, Dong X. Advanced glycation end products of bovine serum albumin-induced endothelial-to-mesenchymal transition in cultured human and monkey endothelial cells via protein kinase b signaling cascades. Mol Vis. 2010;16:2669–2679.
39. Maines LW, French KJ, Wolpert EB, et al. Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci. 2006;47(11):5022–5031.
40. Mammadzada P, Gudmundsson J, Kvanta A, et al. Differential hypoxic response of human choroidal and retinal endothelial cells proposes tissue heterogeneity of ocular angiogenesis. Acta Ophthalmol (Copenh). 2016;94(8):805–814.
41. Miller EC, Capps BE, Sanghani RR, et al. Regulation of IGF-I signaling in retinal endothelial cells by hyperglycemia. Invest Ophthalmol Vis Sci. 2007;48(8):3878–3887.
42. Nawaz MI, Van Raemdonck K, Mohammad G, et al. Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy. Exp Eye Res. 2013;109:67–76.
43. Opreanu M, Lydic TA, Reid GE, et al. Inhibition of cytokine signaling in human retinal endothelial cells through downregulation of sphingomyelinases by docosahexaenoic acid. Invest Ophthalmol Vis Sci. 2010;51(6):3253–3263.
44. Spoerri PE, Afzal A, Li Calzi S, et al. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells. Mol Vis. 2006;12:32–42.
45. Steinle JJ, Chin VC, Williams KP, et al. Beta-adrenergic receptor stimulation modulates iNOS protein levels through p38 and ERK1/2 signaling in human retinal endothelial cells. Exp Eye Res. 2008;87(1):30–34.
46. Su T, Gillies MC. A simple method for the in vitro culture of human retinal capillary endothelial cells. Invest Ophthalmol Vis Sci. 1992;33(10):2809–2813.
47. Sun J, Xu Y, Sun S, et al. Intermittent high glucose enhances cell proliferation and VEGF expression in retinal endothelial cells: the role of mitochondrial reactive oxygen species. Mol Cell Biochem. 2010;343(1–2):27–35.
48. Trudeau K, Molina AJ, Guo W, et al. High glucose disrupts mitochondrial morphology in retinal endothelial cells: implications for diabetic retinopathy. Am J Pathol. 2010;177(1):447–455.
49. Xiaozhuang Z, Xianqiong L, Jingbo J, et al. Isolation and characterization of fetus human retinal microvascular endothelial cells. Ophthalmic Res. 2010;44(2):125–130.
50. Yamagishi S, Okamoto T, Amano S, et al. Palmitate-induced apoptosis of microvascular endothelial cells and pericytes. Mol Med. 2002;8(4):179–184.
51. Ye EA, Steinle JJ. Mir-15b/16 protects primary human retinal microvascular endothelial cells against hyperglycemia-induced increases in tumor necrosis factor alpha and suppressor of cytokine signaling 3. J Neuroinflammation. 2015;12:44.
52. Sheikpranbabu S, Kalishwaralal K, Venkataraman D, et al. Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells. J Nanobiotechnology. 2009;7:8.
53. Takamura Y, Tomomatsu T, Kubo E, et al. Role of the polyol pathway in high glucose-induced apoptosis of retinal pericytes and proliferation of endothelial cells. Invest Ophthalmol Vis Sci. 2008;49(7):3216–3223.
54. Caprnda M, Kubatka P, Saxena S, et al. The impact of hyperglycemia on VEGF secretion in retinal endothelial cells. Folia Medica. 2017;59(2):183–189.
55. Mondragon AA, Betts-Obregon BS, Moritz RJ, et al. Bigh3 protein and macrophages in retinal endothelial cell apoptosis. Apoptosis. 2015;20(1):29–37.
56. Frank RN, Kinsey VE, Frank KW, et al. In vitro proliferation of endothelial cells from kitten retinal capillaries. Invest Ophthalmol Vis Sci. 1979;18(11):1195–1200.
57. Fan Y, Qiao Y, Huang J, et al. Protective effects of Panax notoginseng Saponins against high glucose-induced oxidative injury in rat retinal capillary endothelial cells. Evid Based Complement Alternat Med. 2016;2016:5326382.
58. Boosani CS, Nalabothula N, Sheibani N, et al. Inhibitory effects of arresten on BFGF-induced proliferation, migration, and matrix metalloproteinase-2 activation in mouse retinal endothelial cells. Curr Eye Res. 2010;35(1):45–55.
59. Su X, Sorenson CM, Sheibani N. Isolation and characterization of murine retinal endothelial cells. Mol Vis. 2003;9:171–178.
60. Antonetti DA, Wolpert EB. Isolation and characterization of retinal endothelial cells. Methods Mol Med. 2003;89:365–374.
61. Schor AM, Schor SL. The isolation and culture of endothelial cells and pericytes from the bovine retinal microvasculature: a comparative study with large vessel vascular cells. Microvasc Res. 1986;32(1):21–38.
62. Matsubara TA, Murata TA, Wu GS, et al. Isolation and culture of rat retinal microvessel endothelial cells using magnetic beads coated with antibodies to pecam-1. Curr Eye Res. 2000;20(1):1–7.
63. Chen X, Li J, Li M, et al. Kh902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF. Diabetes Obes Metab. 2013;15(3):224–233.
64. Duffy A, Liew A, O’Sullivan J, et al. Distinct effects of high-glucose conditions on endothelial cells of macrovascular and microvascular origins. Endothelium. 2006;13(1):9–16.
65. Giannini S, Cresci B, Pala L, et al. IGFBPS modulate IGF-I- and high glucose-controlled growth of human retinal endothelial cells. J Endocrinol. 2001;171(2):273–284.
66. Li J, Chen X, Xiao W, et al. Mitochondria-targeted antioxidant peptide ss31 attenuates high glucose-induced injury on human retinal endothelial cells. Biochem Biophys Res Commun. 2011;404(1):349–356.
67. Thakran S, Zhang Q, Morales-Tirado V, et al. Pioglitazone restores IGFBP-3 levels through DNA PK in retinal endothelial cells cultured in hyperglycemic conditions. Invest Ophthalmol Vis Sci. 2014;56(1):177–184.
68. Capozzi ME, McCollum GW, Cousins DB, et al. Linoleic acid is a diabetes-relevant stimulator of retinal inflammation in human retinal Muller cells and microvascular endothelial cells. J Diabetes Metab. 2016;7:12.
69. Chen W, Jump DB, Esselman WJ, et al. Inhibition of cytokine signaling in human retinal endothelial cells through modification of caveolae/lipid rafts by docosahexaenoic acid. Invest Ophthalmol Vis Sci. 2007;48(1):18–26.
70. Delton-Vandenbroucke I, Grammas P, Anderson RE. Polyunsaturated fatty acid metabolism in retinal and cerebral microvascular endothelial cells. J Lipid Res. 1997;38(1):147–159.
71. Delton-Vandenbroucke I, Grammas P, Anderson RE. Regulation of n-3 and n-6 fatty acid metabolism in retinal and cerebral microvascular endothelial cells by high glucose. J Neurochem. 1998;70(2):841–849.
72. Lecomte M, Paget C, Ruggiero D, et al. Docosahexaenoic acid is a major n-3 polyunsaturated fatty acid in bovine retinal microvessels. J Neurochem. 1996;66(5):2160–2167.
73. Hammer SS, Beli E, Kady N, et al. The mechanism of diabetic retinopathy pathogenesis unifying key lipid regulators, sirtuin 1 and liver x receptor. EBioMedicine. 2017;22:181–190.
74. Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol. 2004;88(10):1343–1347.
75. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463–23467.
76. Xie J, Liu X, Li Y, et al. Validation of RT-qPCR reference genes and determination of robo4 expression levels in human retinal endothelial cells under hypoxia and/or hyperglycemia. Gene. 2016;585(1):135–142.
77. Wang D, Wang L, Gu J, et al. Scutellarin inhibits high glucose-induced and hypoxia-mimetic agent-induced angiogenic effects in human retinal endothelial cells through reactive oxygen species/hypoxia-inducible factor-1alpha/vascular endothelial growth factor pathway. J Cardiovasc Pharmacol. 2014;64(3):218–227.
78. Chan PS, Kanwar M, Kowluru RA. Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J Diabetes Complications. 2010;24(1):55–63.
79. Madsen-Bouterse SA, Mohammad G, Kanwar M, et al. Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxid Redox Signal. 2010;13(6):797–805.
80. Santos JM, Kowluru RA. Impaired transport of mitochondrial transcription factor A (TFAM) and the metabolic memory phenomenon associated with the progression of diabetic retinopathy. Diabetes Metab Res Rev. 2013;29(3):204–213.
81. Zhong Q, Kowluru RA. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes. 2011;60(4):1304–1313.
82. Diaz-Coranguez M, Chao DL, Salero EL, et al. Cell autonomous sonic hedgehog signaling contributes to maintenance of retinal endothelial tight junctions. Exp Eye Res. 2017;164:82–89.
83. Samra YA, Saleh HM, Hussein KA, et al. Adenosine deaminase-2-induced hyperpermeability in human retinal vascular endothelial cells is suppressed by microRNA-146b-3p. Invest Ophthalmol Vis Sci. 2017;58(2):933–943.
84. Xie J, Gong Q, Liu X, et al. Transcription factor SP1 mediates hyperglycemia-induced upregulation of roundabout4 in retinal microvascular endothelial cells. Gene. 2017;616:31–40.
85. Castellon R, Caballero S, Hamdi HK, et al. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol Vis Sci. 2002;43(8):2758–2766.
86. Kielczewski JL, Jarajapu YP, McFarland EL, et al. Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res. 2009;105(9):897–905.
87. Kielczewski JL, Li Calzi S, Shaw LC, et al. Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (asmase). Invest Ophthalmol Vis Sci. 2011;52(11):8278–8286.
88. Li Calzi S, Purich DL, Chang KH, et al. Carbon monoxide and nitric oxide mediate cytoskeletal reorganization in microvascular cells via vasodilator-stimulated phosphoprotein phosphorylation: evidence for blunted responsiveness in diabetes. Diabetes. 2008;57(9):2488–2494.
89. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest. 1996;97(12):2883–2890.
90. Munjal ID, McLean NV, Grant MB, et al. Differences in the synthesis of secreted proteins in human retinal endothelial cells of diabetic and nondiabetic origin. Curr Eye Res. 1994;13(4):303–310.
91. Tikhonenko M, Lydic TA, Opreanu M, et al. N-3 polyunsaturated fatty acids prevent diabetic retinopathy by inhibition of retinal vascular damage and enhanced endothelial progenitor cell reparative function. PLoS One. 2013;8(1):e55177.
92. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing sp1 glycosylation. Proc Natl Acad Sci U S A. 2000;97(22):12222–12226.
93. Du Y, Miller CM, Kern TS. Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med. 2003;35(11):1491–1499.
94. Gao J, Zheng Z, Gu Q, et al. Deacetylation of MnSOD by PARP-regulated SIRT3 protects retinal capillary endothelial cells from hyperglycemia-induced damage. Biochem Biophys Res Commun. 2016;472(3):425–431.
95. Lopez-Quintero SV, Cancel LM, Pierides A, et al. High glucose attenuates shear-induced changes in endothelial hydraulic conductivity by degrading the glycocalyx. PLoS One. 2013;8(11):e78954.
96. Perrone L, Devi TS, Hosoya K, et al. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol. 2009;221(1):262–272.
97. Zhang Y, Qu Y, Niu T, et al. O-GLcNAc modification of Sp1 mediates hyperglycaemia-induced ICAM-1 up-regulation in endothelial cells. Biochem Biophys Res Commun. 2017;484(1):79–84.
98. Castilho A, Aveleira CA, Leal EC, et al. Heme oxygenase-1 protects retinal endothelial cells against high glucose- and oxidative/nitrosative stress-induced toxicity. PLoS One. 2012;7(8):e42428.
99. Dagher Z, Gerhardinger C, Vaz J, et al. The increased transforming growth factor-beta signaling induced by diabetes protects retinal vessels. Am J Pathol. 2017;187(3):627–638.
100. el-Remessy AB, Bartoli M, Platt DH, et al. Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci. 2005;118(Pt 1):243–252.
101. Leal EC, Aveleira CA, Castilho AF, et al. High glucose and oxidative/nitrosative stress conditions induce apoptosis in retinal endothelial cells by a caspase-independent pathway. Exp Eye Res. 2009;88(5):983–991.
102. Li J, Wang P, Yu S, et al. Calcium entry mediates hyperglycemia-induced apoptosis through Ca(2+)/calmodulin-dependent kinase ii in retinal capillary endothelial cells. Mol Vis. 2012;18:2371–2379.
103. Betts-Obregon BS, Mondragon AA, Mendiola AS, et al. TGFbeta induces bigh3 expression and human retinal pericyte apoptosis: a novel pathway of diabetic retinopathy. Eye. 2016;30(12):1639–1647.
104. Devi TS, Hosoya K, Terasaki T, et al. Critical role of TXNIP in oxidative stress, DNA damage and retinal pericyte apoptosis under high glucose: implications for diabetic retinopathy. Exp Cell Res. 2013;319(7):1001–1012.
105. Ding L, Cheng R, Hu Y, et al. Peroxisome proliferator-activated receptor alpha protects capillary pericytes in the retina. Am J Pathol. 2014;184(10):2709–2720.
106. Fu D, Wu M, Zhang J, et al. Mechanisms of modified LDL-induced pericyte loss and retinal injury in diabetic retinopathy. Diabetologia. 2012;55(11):3128–3140.
107. Fu D, Yu JY, Yang S, et al. Survival or death: a dual role for autophagy in stress-induced pericyte loss in diabetic retinopathy. Diabetologia. 2016;59(10):2251–2261.
108. Song W, Barth JL, Lu K, et al. Effects of modified low-density lipoproteins on human retinal pericyte survival. Ann N Y Acad Sci. 2005;1043:390–395.
109. Platania CBM, Giurdanella G, Di Paola L, et al. P2X7 receptor antagonism: implications in diabetic retinopathy. Biochem Pharmacol. 2017;138:130–139.
110. Durham JT, Dulmovits BM, Cronk SM, et al. Pericyte chemomechanics and the angiogenic switch: insights into the pathogenesis of proliferative diabetic retinopathy? Invest Ophthalmol Vis Sci. 2015;56(6):3441–3459.
111. Chavira-Suarez E, Sandoval A, Felix R, et al. Expression and high glucose-mediated regulation of k+ channel interacting protein 3 (KChIP3) and KV4 channels in retinal Muller glial cells. Biochem Biophys Res Commun. 2011;404(2):678–683.
112. Cheng L, Bu H, Portillo JA, et al. Modulation of retinal Muller cells by complement receptor C5aR. Invest Ophthalmol Vis Sci. 2013;54(13):8191–8198.
113. Fu D, Yu JY, Connell AR, et al. Beneficial effects of berberine on oxidized LDL-induced cytotoxicity to human retinal Muller cells. Invest Ophthalmol Vis Sci. 2016;57(7):3369–3379.
114. Jayaguru P, Mohr S. Nuclear GAPDH: changing the fate of Muller cells in diabetes. J Ocul Biol Dis Infor. 2011;4(1–2):34–41.
115. Kida T, Ikeda T, Nishimura M, et al. Renin-angiotensin system in proliferative diabetic retinopathy and its gene expression in cultured human Muller cells. Jpn J Ophthalmol. 2003;47(1):36–41.
116. Kusner LL, Sarthy VP, Mohr S. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Muller cells. Invest Ophthalmol Vis Sci. 2004;45(5):1553–1561.
117. Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest Ophthalmol Vis Sci. 2002;43(9):3109–3116.
118. Puro DG. Diabetes-induced dysfunction of retinal Muller cells. Trans Am Ophthalmol Soc. 2002;100:339–352.
119. Shen X, Zhong Y, Xie B, et al. Pigment epithelium derived factor as an anti-inflammatory factor against decrease of glutamine synthetase expression in retinal Muller cells under high glucose conditions. Graefes Arch Clin Exp Ophthalmol. 2010;248(8):1127–1136.
120. Tien T, Zhang J, Muto T, et al. High glucose induces mitochondrial dysfunction in retinal Muller cells: implications for diabetic retinopathy. Invest Ophthalmol Vis Sci. 2017;58(7):2915–2921.
121. Tretiach M, Madigan MC, Gillies MC. Conditioned medium from mixed retinal pigmented epithelium and Muller cell cultures reduces in vitro permeability of retinal vascular endothelial cells. Br J Ophthalmol. 2004;88(7):957–961.
122. Wang LL, Chen H, Huang K, et al. Elevated histone acetylations in Muller cells contribute to inflammation: a novel inhibitory effect of minocycline. Glia. 2012;60(12):1896–1905.
123. Wu M, Yang S, Elliott MH, et al. Oxidative and endoplasmic reticulum stresses mediate apoptosis induced by modified LDL in human retinal Muller cells. Invest Ophthalmol Vis Sci. 2012;53(8):4595–4604.
124. Gaucher D, Chiappore JA, Paques M, et al. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res. 2007;47(5):612–623.
125. Portillo JC, Lopez Corcino Y, Miao Y, et al. CD40 in retinal Muller cells induces P2X7-dependent cytokine expression in macrophages/microglia in diabetic mice and development of early experimental diabetic retinopathy. Diabetes. 2017;66(2):483–493.
126. Ding X, Zhang M, Gu R, et al. Activated microglia induce the production of reactive oxygen species and promote apoptosis of co-cultured retinal microvascular pericytes. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):777–788.
127. Dunn KC, Aotaki-Keen AE, Putkey FR, et al. Arpe-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res. 1996;62(2):155–169.
128. Luo Y, Zhuo Y, Fukuhara M, et al. Effects of culture conditions on heterogeneity and the apical junctional complex of the ARPE-19 cell line. Invest Ophthalmol Vis Sci. 2006;47(8):3644–3655.
129. Calado SM, Alves LS, Simao S, et al. GLUT1 activity contributes to the impairment of PEDF secretion by the RPE. Mol Vis. 2016;22:761–770.
130. Chang ML, Chiu CJ, Shang F, et al. High glucose activates ChREBP-mediated HIF-1alpha and VEGF expression in human RPE cells under normoxia. Adv Exp Med Biol. 2014;801:609–621.
131. Du M, Wu M, Fu D, et al. Effects of modified LDL and HDL on retinal pigment epithelial cells: a role in diabetic retinopathy? Diabetologia. 2013;56(10):2318–2328.
132. Kim DI, Park MJ, Choi JH, et al. Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis. Int J Biochem Cell Biol. 2015;59:41–51.
133. Li X, Cai Y, Wang YS, et al. Hyperglycaemia exacerbates choroidal neovascularisation in mice via the oxidative stress-induced activation of STAT3 signalling in RPE cells. PLoS One. 2012;7(10):e47600.
134. Winkler J, Hoerauf H. TGF-ss and RPE-derived cells in taut subretinal strands from patients with proliferative vitreoretinopathy. Eur J Ophthalmol. 2011;21(4):422–426.
135. Xu HZ, Song Z, Fu S, et al. RPE barrier breakdown in diabetic retinopathy: seeing is believing. J Ocul Biol Dis Infor. 2011;4(1–2):83–92.
136. Foresti R, Bucolo C, Platania CM, et al. Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. Pharmacol Res. 2015;99:296–307.
137. Henry DN, Frank RN, Hootman SR, et al. Glucose-specific regulation of aldose reductase in human retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci. 2000;41(6):1554–1560.
138. Farnoodian M, Halbach C, Slinger C, et al. High glucose promotes the migration of retinal pigment epithelial cells through increased oxidative stress and PEDF expression. Am J Physiol Cell Physiol. 2016;311(3):C418–C436.
139. Liu Y, Leo LF, McGregor C, et al. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Mol Med. 2012;18:1387–1401.
140. Krishnamoorthy RR, Clark AF, Daudt D, et al. A forensic path to RGC-5 cell line identification: lessons learned. Invest Ophthalmol Vis Sci. 2013;54(8):5712–5719.
141. Skaper SD. Rodent retinal ganglion cell cultures. Methods Mol Biol. 2012;846:117–129.
142. Fuchs C, Forster V, Balse E, et al. Retinal-cell-conditioned medium prevents TNF-alpha-induced apoptosis of purified ganglion cells. Invest Ophthalmol Vis Sci. 2005;46(8):2983–2991.
143. Unterlauft JD, Claudepierre T, Schmidt M, et al. Enhanced survival of retinal ganglion cells is mediated by Muller glial cell-derived PEDF. Exp Eye Res. 2014;127:206–214.
144. McCaffery CA, Bennett MR, Dreher B. The survival of neonatal rat retinal ganglion cells in vitro is enhanced in the presence of appropriate parts of the brain. Exp Brain Res. 1982;48(3):377–386.
145. Ha Y, Saul A, Tawfik A, et al. Diabetes accelerates retinal ganglion cell dysfunction in mice lacking sigma receptor 1. Mol Vis. 2012;18:2860–2870.
146. Tan E, Ding XQ, Saadi A, et al. Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest Ophthalmol Vis Sci. 2004;45(3):764–768.
147. Balmer D, Emery M, Andreux P, et al. Autophagy defect is associated with low glucose-induced apoptosis in 661w photoreceptor cells. PLoS One. 2013;8(9):e74162.
148. Lupo G, Motta C, Giurdanella G, et al. Role of phospholipases a2 in diabetic retinopathy: in vitro and in vivo studies. Biochem Pharmacol. 2013;86(11):1603–1613.
149. Watanabe S, Morisaki N, Tezuka M, et al. Cultured retinal pericytes stimulate in vitro angiogenesis of endothelial cells through secretion of a fibroblast growth factor-like molecule. Atherosclerosis. 1997;130(1–2):101–107.
150. Wang Q, Navitskaya S, Chakravarthy H, et al. Dual anti-inflammatory and anti-angiogenic action of miR-15a in diabetic retinopathy. EBioMedicine. 2016;11:138–150.
151. Caballero S, Sengupta N, Afzal A, et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes. 2007;56(4):960–967.
152. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996;84(3):491–495.
153. Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Exp Anim. 1980;29(1):1–13.
154. Thayer TC, Wilson SB, Mathews CE. Use of nonobese diabetic mice to understand human type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):541–561.
155. Engerman RL, Bloodworth JM, Jr. Experimental diabetic retinopathy in dogs. Arch Ophthalmol. 1965;73:205–210.
156. Goldsmith JR, Jobin C. Think small: zebrafish as a model system of human pathology. J Biomed Biotechnol. 2012;2012:817341.
157. Tso MO, Kurosawa A, Benhamou E, et al. Microangiopathic retinopathy in experimental diabetic monkeys. Trans Am Ophthalmol Soc. 1988;86:389–421.
158. Weerasekera LY, Balmer LA, Ram R, et al. Characterization of retinal vascular and neural damage in a novel model of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2015;56(6):3721–3730.
159. Feit-Leichman RA, Kinouchi R, Takeda M, et al. Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes. Invest Ophthalmol Vis Sci. 2005;46(11):4281–4287.
160. Amadio M, Pascale A, Cupri S, et al. Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacol Res. 2016;111:713–720.
161. Martin PM, Roon P, Van Ells TK, et al. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci. 2004;45(9):3330–3336.
162. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. Faseb J. 2002;16(3):438–440.
163. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160(2):501–509.
164. Engerman RL, Kern TS. Experimental galactosemia produces diabetic-like retinopathy. Diabetes. 1984;33(1):97–100.
165. Kern TS, Engerman RL. A mouse model of diabetic retinopathy. Arch Ophthalmol. 1996;114(8):986–990.
166. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(1):101–111.
167. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46(6):2210–2218.
168. Robinson R, Barathi VA, Chaurasia SS, et al. Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis Model Mech. 2012;5(4):444–456.
169. Lee S, Harris NR. Losartan and ozagrel reverse retinal arteriolar constriction in non-obese diabetic mice. Microcirculation. 2008;15(5):379–387.
170. Midena E, Segato T, Radin S, et al. Studies on the retina of the diabetic db/db mouse. I. Endothelial cell-pericyte ratio. Ophthalmic Res. 1989;21(2):106–111.
171. Tadayoni R, Paques M, Gaudric A, et al. Erythrocyte and leukocyte dynamics in the retinal capillaries of diabetic mice. Exp Eye Res. 2003;77(4):497–504.
172. Ellis EA, Guberski DL, Hutson B, et al. Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat. Nitric Oxide. 2002;6(3):295–304.
173. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009;127(4):533–540.
174. Klein R, Cruickshanks KJ, Myers CE, et al. The relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration: the Beaver Dam studies. Ophthalmology. 2013;120(5):1012–1019.
175. Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects Med. 2012;33(4):295–317.
176. Malek G, Lad EM. Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration. Cell Mol Life Sci. 2014;71(23):4617–4636.
177. Sohrab MA, Smith RT, Fawzi AA. Imaging characteristics of dry age-related macular degeneration. Semin Ophthalmol. 2011;26(3):156–166.
178. Curcio CA, Millican CL. Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch Ophthalmol. 1999;117(3):329–339.
179. Green WR, Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman lecture. Ophthalmology. 1993;100(10):1519–1535.
180. Loffler KU, Lee WR. Basal linear deposit in the human macula. Graefes Arch Clin Exp Ophthalmol. 1986;224(6):493–501.
181. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1996;37(7):1236–1249.
182. Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012;75(1):26–39.
183. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet. 2012;379(9827):1728–1738.
184. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40(3):352–368.
185. Johnson LV, Forest DL, Banna CD, et al. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(45):18277–18282.
186. Pilgrim MG, Lengyel I, Lanzirotti A, et al. Subretinal pigment epithelial deposition of drusen components including hydroxyapatite in a primary cell culture model. Invest Ophthalmol Vis Sci. 2017;58(2):708–719.
187. Galloway CA, Dalvi S, Hung SSC, et al. Drusen in patient-derived hiPSC-RPE models of macular dystrophies. Proc Natl Acad Sci U S A. 2017;114:E8214-E8223.
188. Fletcher EL, Jobling AI, Greferath U, et al. Studying age-related macular degeneration using animal models. Optom Vis Sci. 2014;91(8):878–886.
189. Pennesi ME, Neuringer M, Courtney RJ. Animal models of age related macular degeneration. Mol Aspects Med. 2012;33(4):487–509.
190. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res. 2010;29(6):500–519.
191. Ramkumar HL, Zhang J, Chan CC. Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD). Prog Retin Eye Res. 2010;29(3):169–190.
192. Zeiss CJ. Animals as models of age-related macular degeneration: an imperfect measure of the truth. Vet Pathol. 2010;47(3):396–413.
193. Edwards AO, Malek G. Molecular genetics of AMD and current animal models. Angiogenesis. 2007;10(2):119–132.
194. Marmorstein AD, Marmorstein LY. The challenge of modeling macular degeneration in mice. Trends Genet. 2007;23(5):225–231.
195. Fritsche LG, Fariss RN, Stambolian D, et al. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. 2014;15:151–171.
196. Gerth C. The role of the ERG in the diagnosis and treatment of age-related macular degeneration. Doc Ophthalmol. 2009;118(1):63–68.
197. Tao Y, Jiang P, Wei Y, et al. Alpha-lipoic acid treatment improves vision-related quality of life in patients with dry age-related macular degeneration. Tohoku J Exp Med. 2016;240(3):209–214.
198. Ramkumar HL, Tuo J, Shen DF, et al. Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease a2e accumulation and vegf expression in the retinas of ccl2/cx3cr1-deficient mice on crb1rd8 background. J Nutr. 2013;143(7):1129–1135.
199. Shen D, Cao X, Zhao L, et al. Naloxone ameliorates retinal lesions in Ccl2/Cx3cr1 double-deficient mice via modulation of microglia. Invest Ophthalmol Vis Sci. 2011;52(6):2897–2904.
200. Kim SJ, Lee HJ, Yun JH, et al. Intravitreal tsg-6 suppresses laser-induced choroidal neovascularization by inhibiting ccr2+ monocyte recruitment. Sci Rep. 2015;5:11872.
201. Ren X, Li J, Xu X, et al. Ibi302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys. Exp Eye Res. 2016;145:352–358.
202. Jo DH, Kim JH, Yang W, et al. Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization. Oncotarget. 2017;8(28):45506–45516.
203. Loyet KM, Good J, Davancaze T, et al. Complement inhibition in cynomolgus monkeys by anti-factor D antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration. J Pharmacol Exp Ther. 2014;351(3):527–537.
204. Cai J, Nelson KC, Wu M, et al. Oxidative damage and protection of the RPE. Prog Retin Eye Res. 2000;19(2):205–221.
205. Wenzel A, Grimm C, Samardzija M, et al. Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration. Prog Retin Eye Res. 2005;24(2):275–306.
206. Cruickshanks KJ, Hamman RF, Klein R, et al. The prevalence of age-related maculopathy by geographic region and ethnicity. The Colorado-Wisconsin study of age-related maculopathy. Arch Ophthalmol. 1997;115(2):242–250.
207. Vingerling JR, Hofman A, Grobbee DE, et al. Age-related macular degeneration and smoking. The Rotterdam study. Arch Ophthalmol. 1996;114(10):1193–1196.
208. Behndig A, Svensson B, Marklund SL, et al. Superoxide dismutase isoenzymes in the human eye. Invest Ophthalmol Vis Sci. 1998;39(3):471–475.
209. Imamura Y, Noda S, Hashizume K, et al. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in sod1-deficient mice: a model of age-related macular degeneration. Proc Natl Acad Sci U S A. 2006;103(30):11282–11287.
210. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99(23):14682–14687.
211. Hashizume K, Hirasawa M, Imamura Y, et al. Retinal dysfunction and progressive retinal cell death in SOD1-deficient mice. Am J Pathol. 2008;172(5):1325–1331.
212. Kimura K, Isashiki Y, Sonoda S, et al. Genetic association of manganese superoxide dismutase with exudative age-related macular degeneration. Am J Ophthalmol. 2000;130(6):769–773.
213. Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet. 1995;11(4):376–381.
214. Justilien V, Pang JJ, Renganathan K, et al. SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci. 2007;48(10):4407–4420.
215. Cousins SW, Espinosa-Heidmann DG, Alexandridou A, et al. The role of aging, high fat diet and blue light exposure in an experimental mouse model for basal laminar deposit formation. Exp Eye Res. 2002;75(5):543–553.
216. Espinosa-Heidmann DG, Suner IJ, Catanuto P, et al. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest Ophthalmol Vis Sci. 2006;47(2):729–737.
217. Fujihara M, Nagai N, Sussan TE, et al. Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigmented epithelial cells in mice. PLoS One. 2008;3(9):e3119.
218. Wang AL, Neufeld AH. Smoking mice: a potential model for studying accumulation of drusen-like material on Bruch’s membrane. Vision Res. 2010;50(7):638–642.
219. Hu P, Herrmann R, Bednar A, et al. Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathology. Proc Natl Acad Sci U S A. 2013;110(43):E4069–E4078.
220. Kim SY, Yang HJ, Chang YS, et al. Deletion of aryl hydrocarbon receptor AHR in mice leads to subretinal accumulation of microglia and RPE atrophy. Invest Ophthalmol Vis Sci. 2014;55(9):6031–6040.
221. Choudhary M, Kazmin D, Hu P, et al. Aryl hydrocarbon receptor knock-out exacerbates choroidal neovascularization via multiple pathogenic pathways. J Pathol. 2015;235(1):101–112.
222. Klein R, Klein BE, Tomany SC, et al. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology. 2003;110(6):1273–1280.
223. van Leeuwen R, Ikram MK, Vingerling JR, et al. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam study. Invest Ophthalmol Vis Sci. 2003;44(9):3771–3777.
224. Curcio CA, Millican CL, Bailey T, et al. Accumulation of cholesterol with age in human Bruch’s membrane. Invest Ophthalmol Vis Sci. 2001;42(1):265–274.
225. Pauleikhoff D, Harper CA, Marshall J, et al. Aging changes in Bruch’s membrane. A histochemical and morphologic study. Ophthalmology. 1990;97(2):171–178.
226. Sheraidah G, Steinmetz R, Maguire J, et al. Correlation between lipids extracted from Bruch’s membrane and age. Ophthalmology. 1993;100(1):47–51.
227. Li CM, Chung BH, Presley JB, et al. Lipoprotein-like particles and cholesteryl esters in human Bruch’s membrane: initial characterization. Invest Ophthalmol Vis Sci. 2005;46(7):2576–2586.
228. Mares-Perlman JA, Brady WE, Klein R, et al. Dietary fat and age-related maculopathy. Arch Ophthalmol. 1995;113(6):743–748.
229. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol. 2003;121(12):1728–1737.
230. Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein e with age-related macular degeneration. Am J Hum Genet. 1998;63(1):200–206.
231. Simonelli F, Margaglione M, Testa F, et al. Apolipoprotein e polymorphisms in age-related macular degeneration in an Italian population. Ophthalmic Res. 2001;33(6):325–328.
232. Cousins SW, Marin-Castano ME, Espinosa-Heidmann DG, et al. Female gender, estrogen loss, and sub-RPE deposit formation in aged mice. Invest Ophthalmol Vis Sci. 2003;44(3):1221–1229.
233. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71(2):343–353.
234. Dithmar S, Curcio CA, Le NA, et al. Ultrastructural changes in Bruch’s membrane of apolipoprotein E-deficient mice. Invest Ophthalmol Vis Sci. 2000;41(8):2035–2042.
235. Malek G, Johnson LV, Mace BE, et al. Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci U S A. 2005;102(33):11900–11905.
236. Malek G, Mace B, Saloupis P, et al. Initial observations of key features of age-related macular degeneration in ApoE targeted replacement mice. Adv Exp Med Biol. 2006;572:109–117.
237. Sullivan PM, Mezdour H, Aratani Y, et al. Targeted replacement of the mouse apolipoprotein e gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272(29):17972–17980.
238. Malek G, Li CM, Guidry C, et al. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol. 2003;162(2):413–425.
239. Espinosa-Heidmann DG, Sall J, Hernandez EP, et al. Basal laminar deposit formation in APO B100 transgenic mice: complex interactions between dietary fat, blue light, and vitamin E. Invest Ophthalmol Vis Sci. 2004;45(1):260–266.
240. Fujihara M, Bartels E, Nielsen LB, et al. A human APOB100 transgenic mouse expresses human APOB100 in the RPE and develops features of early AMD. Exp Eye Res. 2009;88(6):1115–1123.
241. Sallo FB, Bereczki E, Csont T, et al. Bruch’s membrane changes in transgenic mice overexpressing the human biglycan and apolipoprotein B-100 genes. Exp Eye Res. 2009;89(2):178–186.
242. Choudhary M, Ding JD, Qi X, et al. PPARbeta/delta selectively regulates phenotypic features of age-related macular degeneration. Aging (Albany NY). 2016;8(9):1952–1978.
243. Priya RR, Chew EY, Swaroop A. Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management. Ophthalmology. 2012;119(12):2526–2536.
244. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102(20):7227–7232.
245. Edwards AO, Ritter R, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308(5720):421–424.
246. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385–389.
247. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308(5720):419–421.
248. Mullins RF, Russell SR, Anderson DH, et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. Faseb J. 2000;14(7):835–846.
249. Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2009;93(5):610–613.
250. Chen H, Yu KD, Xu GZ. Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis. PLoS One. 2012;7(8):e42464.
251. Coffey PJ, Gias C, McDermott CJ, et al. Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proc Natl Acad Sci U S A. 2007;104(42):16651–16656.
252. Williams JA, Greenwood J, Moss SE. Retinal changes precede visual dysfunction in the complement factor H knockout mouse. PLoS One. 2013;8(7):e68616.
253. Ufret-Vincenty RL, Aredo B, Liu X, et al. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. Invest Ophthalmol Vis Sci. 2010;51(11):5878–5887.
254. Toomey CB, Kelly U, Saban DR, et al. Regulation of age-related macular degeneration-like pathology by complement factor H. Proc Natl Acad Sci U S A. 2015;112(23):E3040–E3049.
255. Ding JD, Kelly U, Landowski M, et al. Expression of human complement factor H prevents age-related macular degeneration-like retina damage and kidney abnormalities in aged CFH knockout mice. Am J Pathol. 2015;185(1):29–42.
256. Lyzogubov VV, Tytarenko RG, Jha P, et al. Role of ocular complement factor H in a murine model of choroidal neovascularization. Am J Pathol. 2010;177(4):1870–1880.
257. Rohrer B, Long Q, Coughlin B, et al. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50(7):3056–3064.
258. Guymer RH, Tao LW, Goh JK, et al. Identification of urinary biomarkers for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(7):4639–4644.
259. Combadiere C, Feumi C, Raoul W, et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest. 2007;117(10):2920–2928.
260. Tuo J, Bojanowski CM, Zhou M, et al. Murine CCL2/CX3CR1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48(8):3827–3836.
261. Vessey KA, Greferath U, Jobling AI, et al. Ccl2/cx3cr1 knockout mice have inner retinal dysfunction but are not an accelerated model of AMD. Invest Ophthalmol Vis Sci. 2012;53(12):7833–7846.